Betahistine
Treatment for Vertigo
Typical Dosage: 8-16 mg three times daily, up to 48 mg/day
Effectiveness
65%
Safety Score
70%
Clinical Trials
11
Participants
12.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
8-16 mg three times daily, up to 48 mg/day
Time to Effect
Weeks to months for full benefit, some symptomatic relief sooner
Treatment Duration
Long-term, possibly indefinite for chronic conditions
Evidence Quality
MODERATENumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
70%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$270
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$450
Cost per Remission
$675
Prescription Access Economics
Annual Societal Loss per Patient
$170
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$50/year
Travel + wait time
Insurance Admin Cost
$20/year
Prior auth, claims
Rx Price
$200/year
Potential OTC Price
$50/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
MODERATEBetahistine Outcomes
for Vertigo
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
Headache
+12%
Nausea
+7%
Indigestion
+7%
Rash
+3%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Betahistine in Vertigo
Efficacy and Safety of Rimegepant for Acute Dizziness
NCT07435090NOT YET RECRUITINGPHASE2, PHASE3
370 participants
INTERVENTIONAL
Started: Mar 20, 2026
Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV
NCT06001047RECRUITINGNA
120 participants
INTERVENTIONAL
Xi'an, China
Started: Nov 1, 2023
Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation
NCT06001593RECRUITINGPHASE1, PHASE2
120 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 18, 2023
Completed Clinical Trials
7 completed trials for Betahistine in Vertigo
Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo
NCT07075289COMPLETEDPHASE4
44 participants
INTERVENTIONAL
Surakarta, Indonesia
Started: Apr 1, 2024
Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice
NCT01759251COMPLETED
309 participants
OBSERVATIONAL
Belgorod, Russia +23 more
Started: Jan 1, 2013
AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery
NCT03908567COMPLETEDPHASE2
124 participants
INTERVENTIONAL
Marseille, France
Started: Jul 18, 2019
Paroxysmal Positional Vertigo & Repositioning Maneuvers
NCT05309538COMPLETEDNA
90 participants
INTERVENTIONAL
Islamabad, Pakistan
Started: Jan 2, 2021
Safety and Efficacy of Shi's Traumatology Osteopathic Manipulative Treatment for Cervicogenic Dizziness
NCT05604937COMPLETEDNA
114 participants
INTERVENTIONAL
Shanghai, China +2 more
Started: Feb 14, 2023
Brain Structural Abnormalities in Patients With Vertigo
NCT06848712COMPLETED
464 participants
OBSERVATIONAL
Budapest, Hungary
Started: Sep 1, 2020
Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Benign Paroxysmal Positional Vertigo
NCT01969513COMPLETEDNA
153 participants
INTERVENTIONAL
L'Hospitalet de Llobregat, Spain
Started: Nov 1, 2012